Bortezomib treatment was able to restore FoxO3a expression, sensitize BCR-ABL T315I expressing cells to apoptosis, and inhibit CML-like disease in leukemic mice [160]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.